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Blunting of the hypoxemia-induced decrease in GFR by the intrarenal
infusion of ANP. P.H. Wiesel, B.A. Semmekrot, f-P. Guignard,
Service de Pédiatrie, CHUV - 1011, Lausanne, Switzerland. Hypox-
emia, as seen in severe respiratory distress, can profoundly affect renal
function. In animal models, acute hypoxemia induces renal vasocon-
striction, with a concomitant decrease in diuresis, glomerular filtration
rate (GFR) and renal blood flow (RBF). The effect of atrial natriuretic
peptide (ANP), a hormone with potent diuretic, natriuretic and vasodi-
lating properties, was investigated in adult rabbits undergoing acute
hypoxemia. Renal functions of the right control kidney and left saline-
infused kidney were separately assessed in 7 anesthetized and mechan-
ically ventilated animals. Inulin and PAH clearances were used as
indices of GFR and RBF, respectively. Throughout the experiment,
arterial pH, pCO2 and HCO3 remained unchanged. During a 20-mm
control period (Pa02 = 131 12 mm Hg), GFR, RBF, renal vascular
resistance (RVR) and fractional sodium excretion (FENa) were similar
in both kidneys, diuresis being lower in the left manipulated kidney
(0.22 0.02 vs. 0.17 0.02 mI/kg/mm). The subsequent 20-mm hypoxic
period (Pa02 = 30 1 mm Hg) was associated with a decrease in the
function of the right and left kidneys: diuresis (—38 6% and —36
6%), GFR(—26 5% and —29 6%), RBF(— 17 9% and —29 8%),
RVR (+28 16% and +59 30%) and FENa (—32 12% and —28
8%). Alpha-human ANP infusion in the left renal artery (100 ng/min)
during the second subsequent 20-mm hypoxic period (Pa02 = 30 2
mm Hg) was associated with a marked increase in diuresis (+52 11%)
and FENa (+66 19%). GFR aid RVR returned to normal values. RBF
increased without reaching the tormal value. The function of the right
control kidney remained impaired. Mean arterial pressure declined after
ANP infusion from 101 4 to 93 5 mm Hg. The protective effect of
ANP is probably related to its renal vascular properties. The clinical
relevance of the beneficial effects of alpha-human ANP observed in
experimental conditions remains to be demonstrated.
Urodilatin and dopamine: Therapeutic effects of intravenous infusion
during the maintenance phase of ischemiç renal failure in the rat. S.G.
Shaw, P. Weidmann, Med. Poliklinik, Univ. of Berne, Berne, Switzer-
land. Therapeutic evaluation of atrial natriuretic peptide (ANP) and its
analogues in the clinical treatment of ischemic acute renal failure (ARF)
has been hampered by suggestions of efficacy restricted only to the
early phase and by observations that detrimental reductions in mean
arterial pressure (MAP) often accompany systemic infusion. To evalu-
ate and possibly circumvent these proposed limitations, we assessed
the therapeutic potential of combining intravenous infusion of the
N-terminally extended ANP analogue Urodilatin (UD) with the pressor
agent dopamine (DA) during the maintenance phase of ARF in Sprague-
Dawley rats under pentobarbital anaesthesia. Twenty-four hours after
30-mm of bilateral renal artery clamping, carotid artery, jugular vein
and bladder cannulae were inserted, and separate groups of animals
were infused intravenously for 4 hr with UD (0.67 g/kgImin) plus DA
(0.5 to 5 mg/kg/hr), or DA alone (0.5 to 2.5 mg/ks/hr). Plasma creatinine
(Cr), C14-inulin clearance (GFR), urine flow (UV) hematocrit (HC) and
MAP were monitored. Urine losses were replaced by 0.9% saline. GFR
before infusion averaged 0.41 0.06and was significantly increased (P
<0.001) to 1.1 0.1 mI/mm after 4 hr of UD + DA, Over this time Cr
was reduced from 183 19 to 104 7 mmol/liter (P < 0.001) and UV
increased from 1.4 0.2 to 5.4 0.6 mI/hr (P < 0.001). MAP was
maintained at 120 4 mm Hg. HC was unchanged, Without DA, UD
reduced MAP from 122 4 to 99 4 mm Hg but did not improve renal
function. DA alone did not markedly improve any of the parameters
despite a MAP of 123 2 mm Hg. These data emphasize the
importance of maintaining MAP in any assessment of the therapeutic
potential of ANP or its analogues in ARF, demonstrate the ability of
UD + DA to improve renal function in the established phase of
experimental ARF, and provide a potentially effective practical strategy
for the successful use of these peptides in human ARF.
Late renal sequelae after treatment with cisplatin in children and
adolescents: Frequency and extent. C. Kanaka, M.G. Bianchetti, A.
Ridolfi Lüthy, A. Hirt, H.P. Wagner, E. Peheim, O.H. Oetliker,
Medizinische Kinderklinik und Chemisches Zentrallabor, Inselspital,
CH-3010 Bern, Switzerland. Frequency and extent of late renal se-
quelae after cisplatin have not yet been extensively investigated in
children and adolescents. Nine children or adolescents (aged 4 to 19
years) had previously been treated with combined chemotherapy in-
cluding cisplatin (global dosage ranging from 310 to 1710 mg/rn2)
because of neuroblastoma (N = 4), osteosarcoma (N = 2), rhabdomy-
osarcoma (N = 2) or ependymoma (N = 1). The concomitant use of
cisplatin and aminoglycosides had strictly been avoided to prevent
nephrotoxic interactions. All patients were relapse free, healthy and
without medication 4 to 39 months after achieving the chemotherapeu-
tic treatment. Timed urine and blood specimens were collected to
assess the renal handling of electrolytes, glucose and protein in patients
and in controls. Plasma creatinine, urea, sodium, inorganic phosphorus
and uric acid, and the urinary excretion of sodium, inorganic phospho-
rus, uric acid, glucose and protein were comparable in patients and
controls. Calciuria was reduced in seven patients. Three patients with
hypocalciuria had renal magnesium wasting as well. Hypokalemic
metabolic alkalosis occurred in two of the three patients with magne-
sium loss. The only two normocalciuric patients did not show any
renotubular dysfunction. The severity of sequelae after cisplatin was
graded as stage 0 (absent renotubular dysfunctions; N = 2), stage I
(isolated hypocalciuria; N = 4), stage H (hypocalciuria and magnesium
wasting; N = I) or stage III (hypocalciuria, magnesium wasting and
hypokalemic metabolic alkalosis; N = 2). Conclusions: 1.) Chronic
renotubular dysfunctions occur in two thirds of the children or adoles-
cents treated with cisplatin. 2.) Contrary to the common notion,
hypocalciuria and hypokalemic metabolic alkalosis occur in addition to
renal magnesium wasting. 3.) The most accurate marker of cisplatin
nephropathy is hypocalciuria. 4.) Renal magnesium loss occurs in about
half of the patients with hypocalciuria, while isolated magnesium
wasting occurs rarely (or never). 5.) Mild hypochloremic metabolic
alkalosis often complicates renal magnesium wasting. 6.) The normal
plasma creatinine and urea level suggest a normal glomerular filtration
rate in chronic cisplatin nephropathy.
© 1990 by the International Society of Nephrology
A syndrome of atrial natriuretic factor deficiency and pre-hyperten-
sion. P. Ferrari, P. Weidmann, C. Ferrier, R.J. Piso, J. Wey, S. Shaw,
Medizinische Poliklinik, University of Berne, Berne, Switzerland. Atrial
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natriuretic factor (ANF) seems to play a physiological role in the
regulation of sodium fluid-volume and blood pressure (BP) homeosu-
sis. Recently we described a deficient response of circulatory immu-
noreactive (ir) ANF to sustained high sodium (Na) intake in some
hypertension-prone humans. To test the hypothesis of a familial ANF
deficiency, we investigated plasma irANF and some other variables in
42 normotensive offspring of hypertensive parents (OHyp) and 42 age-,
height- and weight-matched normotensive offspring of normotensive
parents (ONorm). The two groups were further subdivided according to
whether the 24 hr urinary Nalcreatinine (Cr) excretion ratios were < 12
(normal Na intake) or  12 (high Na intake). Comparing the 22 OHyp
and the 21 ONorm on a normal Na intake, 24-hr urinary Na excretion
(138 12 vs. 126 10 mmol/day), Cr(l 10 6 vs. 104 6 mI/mm), BP
(124/79 3/2 vs. 122/76 2/2 mm Hg) and plasma 1rANF (17 2 vs. 22
3 pg/mI) did not differ. Comparing the 20 OHyp and the 21 ONorm on
a high Na intake, z4-hr urinary Na (249 28 and 261 16 mmol/day),
Cr 98 7 vs. 104 5 mI/mm) and BP (125/80 3/3 vs. 129/81 3/2
mm Hg) were also similar; however, irANF was reduced in OHyp as
compared with ONorm (27 5 vs. 42 4 pg/mI, P < 0.05). Plasma
irANF coTelated with 24-hr urinary Na both in OHyp and ONorm (r =
0.62 and r = 0.77, P <0.05 and P <0.0001, respectively). However, the
slope of this relationship was more level in OHyp (0.7 vs. 1.9, z-test =
2.3). We postulate a new endocrine syndrome, characterized by a
relative plasma ANF deficiency during high Na intake in some hyper-
tension-prone humans, This functional &fect occurs as a familial
disturbance and may potentially predispose them to the development of
essential hypertension.
Control of hypertension by verapamil enhances renal damage in a rat
remnant kidney model. F.P. Brunner, H.A. Bock, M. Hermie, G. Thiel,
M.J. Mihatsch, Departments of Internal Medicine, Research and
Pathology, University of Basle, Basle, Switzerland. The effect of
verapamil on the progression of renal damage in remnant kidneys is
controversial. Both protection (Harris et al, Kidney mt 31:41, 1987) and
worsening of renal damage (Brunner et al, Kidney mt 36:969, 1989)
have been reported. To evaluate whether these discrepancies might be
dose dependent, we studied the effect of two different doses of oral
verapamil in female Wistar rats. Starting five weeks after 5/6 nephrec-
tomy, animals were given either a high (100-150 mg/kg/day) or a low
(10-15 mg/kg/day) dose of oral verapamil for 16 weeks. The low oral
dose was chosen to match the s.c. dose (2 x 0.1 mg/kg/day) used by
Harris et al, assuming an oral verapamil bioavailability of some 2%.
Proteinuria and systolic BP (tail plethysmography) were recorded at 4
week intervals. Systolic BP remained unchanged (median 162-185 mm
Hg) throughout the study period in the control and the verapamil low
group. High dose verapamil caused a significant (P < 0.001) and
persistent decrease in systolic BP (median 130-140 mm Hg). Median
proteinuria increased little in the control and slightly more in the
verapamil low group, where it reached twice the baseline level. Despite
control of hypertension, median proteinuria increased rapidly in the
verapamil high group, reaching approximately three times baseline
within 8 weeks (P < 0.05 vs. control). Mortality was greater in the
verapamil high group (6/20) than in controt (1/20, P < 0.05) and
verapamil low (2/20). Mean arterial BP and heart rate measured in the
surviving anesthetized rats before sacrifice were lowered insignificantly
in the veraparnil low (J3P 156 7 mm Hg, HR 393 14) but highly
significantly in the verapamil high (BP 124 3 mm Hg, HR 358 6)
compared to the control group (BP 180 8 mm Hg, HR 422 6). We
conclude that effective control of hypertension by verapamil is associ-
ated with worsening of renal damage in this remnant kidney model.
Potential protection of very low dose verapamil (not detected in the
present study) would not appear to be mediated by systemic hemody-
namic effects.
Ecto 5'-nucleotidase may constitute the main source of renal adenosine.
G. Piec, M. Le Hir, U.C. Dubach, Medizinische Universitäts-Polik-
linik, Kantonsspital Base!, Base!, Switzerland. Adenosine is involved in
the regulation of renal hemodynamics, GFR and the release of renin. It
is mainly produced by hydrolysis of 5'-AMP by 5'-nucleotidase (5'-Nu).
The production of adenosine is greatly increased under conditions of
energy deficit which lead to catabolism of ATP and to accumulation of
5'-AMP. We found three types of5'-NU in the rat kidney which exist in
other organs as well: one membrane-bound and the two others soluble.
It is a matter of discussion which 5'-Nu is responsible for the production
of adenosine. Ecto-5'-Nu has been studied extensively. It is located at
the outer surface of the cell membrane. Its preferred substrate is
5'-AMP. We now characterized the two soluble 5'-Nu (called land II in
this abstract) from high-speed supernatants of homogenates. 5'-Nu I
was isolated by molecular sieving chromatography, 5'-Nu II by chro-
matography on phosphoceliulose and on Sepharose Blue. Like the
ecto-enzyme 5'-Nu I was inhibited by ATP and ADP, and the Km values
of the two enzymes were similar. 5'-Nu 1 could be completely inhibited
by antibodies raised against ecto-5'-Nu. Like ecto-5'-Nu it bound to
concanavalin A-Sepharose. Under some conditions a conversion of
membrane-bound 5'-Nu activity into soluble activity was observed in
vitro. These data suggest that 5'-Nu I originates in vitro by enzymatic
solubilization of the ecto-5'-Nu and thus corresponds to an artefact.
5'-Nu IL was stimulated by physiological concentrations of ATP and
inhibited by physiological concentrations of Pi. Thus it can hardly be
responsible for the increased production of adenosine observed during
the breakdown of ATP in the kidney. Moreover its affinity for 5'-AMP
was much lower than for 5'-IMP, suggesting that the intracellular
pathway for intracellular catabolism of nucleotides occurs via desami-
nation of 5'-AMP to 5'-IMP rather than via its dephosphorylation to
adenosine. In conclusion, the ecto-5'-nucleotidase remains as the most
likely source of adenosine in the kidney.
Hypoxemia-induced renal insufficiency: improvement by WR-2721
given before reoxygenation. A. Pedrotti, J.-Ph. Bonj our, J.-P. Gui gnard,
Service de Pédiatrie, CHUV, 1011 Lausanne, Switzerland. Acute
hypoxemia impairs glomerular filtration rate (GFR) and renal blood flow
(RBF) in animal models. The effect of reoxygenation on the hypoxemia-
induced renal insufficiency was assessed in eleven untreated rabbits
(Group A) and in eight rabbits receiving 75 mg/kg body wt of the organic
phosphorothioate WR-2721 immediately before reoxygenation (Group
B). Studies were performed in anesthetized and mechanically-venti-
lated normocapnic animals. GFR and RBF were estimated by the
standard clearance of inulin and PAH, respectively. Renal vascular
resistance (RVR) was calculated as the blood pressure/RBF ratio.
Severe hypoxemia (Pa02 = 30-35 mm Hg) was maintained for 45 mm by
decreasing the Fi02 in the inspired air. Reoxygenation was achieved by
rapidly increasing the Fi02 so as to maintain normoxemic levels for 60
mm. Results obtained during the control (C), hypoxic (H) and reoxy-
genation (R) periods are shown below (mean SE):
Group A
C H R
V 0.46 0.04 0.37 0.02a 0.41 0.04
GFR 4.28 0.3 3.55 0.3" 3.61 03b
RBF 40.3 2.4 30.3 30.7 3.2c
RVR 2.33 0.2 2.75 0.3 2.64 0.3
FF 16.6 0.7 17.9 1.3 18.3 1.4
Group B
C H R
V 0.42 0.03 0.34 0.03 0.43 0.04
GFR 4.38 0.3 3.62 02b 4.89 o.3
RBF 39,7 2.5 29.7 21b 33.9 2.la
RVR 2.39 0.1 3.04 0.3 2.46 0.2
FF 17.2 0.4 18.7 0.7 22.4 1.3"
(V = mI/kg. mm; GFR = mi/kg . mm; RBF = mI/kg/mm; RVR =
mm Hg/mi/kg. mm; FF =
a P < 0.05; k p < 0.01; P < 0.001: hypoxemia or reoxygenation
versus cOntrol
Results suggest that the renal function changes occurring during acute
severe hypoxemia are not reversed by 60 mm reoxygenation. The
striking improvement seen after reoxygenation in animals administered
WR-272l could be due to the specific properties of WR-2721, an agent
which could a) act as an oxygen free radicals scavenger, b) decrease
oxygen tissue consumption and C) interfere with calcium transmem-
brane transport.
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Urine net charge as an index of urinary ammonium in neonates and
infants. E. Sulyok, J.-P. Guignard, County Children's Hospital, Pécs,
Hungary, and Service de Pédiatrie, CHUV- 1011 Lausanne, Switzer-
land. The present study was undertaken to define the relationship of
urinary anion gap (UGA) to urine NH4 concentration in preterm and
full-term neonates with spontaneous and NH4CI-induced metabolic
acidosis. Studies were performed in 10 premature infants (mean birth
weight: 1618 g; gestational age: 30.8 weeks) weekly for 6 consecutive
weeks, and in II full-term neonates (mean birth weight: 3085 g;
gestational age: 38.6 weeks) on the 7th day of life; and in 25 older
control infants (mean age: 6.5 months; body weight: 6802 g) before and
after NH4CI-loading. Blood acid-base parameters, plasma electrolyte
concentrations, urine pH, NH4, titratable acidity, HCO3, net acid
and electrolyte concentrations were measured, while UAG was calcu-
lated. It was demonstrated that the significant reduction in plasma total
CO2 content induced by NH4CI administration and the subsequent
elevation in urinary NH4 concentration was associated with some
decrease of UAG in each group. In premature infants there was no
relationship between urinary NH4 excretion and UAG during the first
two weeks of life, while from the 3rd week onward a significant negative
correlation could be demonstrated. In one week-old full-term neonates,
UAG also tended to decline with increasing NH4 concentrations; this
relationship, however, failed to achieve statistical significance (r =
0.22, 0.05 <P < 0.01). In the older infants urinary NH4 excretion was
found to correlate negatively with UAG (r =
—0.31; P < 0.05). It is
concluded that due to the marked dynamic changes in unmeasured ionic
composition of neonatal urine, UAG is not a valuable index of urinary
NH4 excretion in newborn infants during the first weeks of life.
Acute uric acid nephropathy (AUAN) in two gouty patients with normal
uric acid production and high urine acidity. B. Hess, U. Binswanger,
Med. Universitätspo!iklinik, Inselspital, Bern, and Nephrologische
Station, Universitätsspital, Zurich, Switzerland. AUAN mostly occurs
in patients with malignant diseases because of greatly elevated serum
uric acid (UA) levels (above 1000 smo1/liter) and hyperuricosuria. In a
few cases, AUAN has been found after epileptic seizures with hyper-
uricemia or due to a marked increase in renal UA secretion with
hypouricemia. Here we present 2 cases with moderate hyperuricemia
and gout who developed AUAN because of pronounced urine acidity
and predisposing cofactors, leading to urinary supersaturation with
respect to undissociated UA (UUA). Case 1. Because of hyperuricemia
(475 tmol/liter) and gout, a 52-year-old man was on uricosuric treat-
ment with benzbromarone (BB). He was a heavy beer drinker (1.2
liter/day). Shortly after increasing daily beer intake to 1.8 liters, he
suffered from bilateral flank pain and gross hematuria, followed by
acute renal failure (ARF). Bilateral ureteric obstruction (BUO) was
excluded by retrograde pyelography (RP), and UA crystals were found
in the urine sediment (US). After hemodialysis and urine alkalinization,
recovery was complete. Metabolic evaluation revealed a morning
fasting urine pH of 4.6, normal 24-hr urine UA excretion, [UUA] above
UA solubility (0.54 mmol/liter), and a 3-fold increase of UVurate/GFR
after re-exposure to BB 100 mg. Calculated [UUA] = [total UA]/(I +
— PK)• Case 2. A 56-year-old man with hyperuricemia (670
mol/liter) and gout (no treatment) was on vacation, when he ate high
amounts of purine-rich foods (meat, fish) against customary habits.
Bilateral flank pain and hematuria, followed by ARF, occurred. BUO
was excluded by RP, and US showed UA crystals. After urine
alkalinization, recovery was complete. Metabolic evaluation revealed a
morning fasting urine pH of 5.0, normal 24-hr urine UA excretion, and
[UUA] above UA solubility. Conclusions: As has been described in
other patients with gout and normal UA production, urine pH in our 2
cases was more acid than in normal controls, thereby raising [UUA]
above UA solubility despite normal 24-hr urine UA excretion (pK of
UA in urine = 5.35). Co-factors increasing UUA supersaturation were
present, namely: uricosuric treatment, purine over-consumption, and
heavy beer drinking. Since purine intake is linearly correlated with UA
excretion, and beer contains large amounts of guanosine (which is
metabolized almost completely to UA), purine-rich meals and heavy
beer drinking increase urine UA excretion. Treatment and prophylaxis
of AUAN in both cases consist mainly of urine alkalinization and
avoidance of superimposed risk factors.
Glomerular hemostatic changes in acute cyclosporin A-intoxicated rats.
P. Ruedin, R. Lemoine, M.N. Peraldi, D. Ruedin, E. Rondeau, J.D.
Sraer, Départements de Médecine et de Pat hologie, Hôpital Cantonal
Universitaire, Geneve, Switzerland, and INSERM U 64, Paris, France.
Cyclosporin A (C5A) has been involved in glomerular thrombi forma-
tion and in the development of thrombotic microangiopathy. To eluci-
date a putative thrombogenic role of CsA, we investigated the effect of
an acute CsA intoxication on rat glomerular hemostatic properties.
Male Sprague-Dawley (SD) were given CsA 50 mg/kg body wt (CsAR)
intraperitoneally once daily or vehicle (sham) for 4 days. Glomerular
procoagulant tissue factor-like activity (GPCA) was assessed by the
ability of potterized glomeruli to reduce plasma clotting time and
glomerular fibrinolytic activity (GFA) on glomerular supernatant by a
radio-enzymatic assay using 1251 fibrin coated tubes. Urokinase (u-PA)
activity was measured spectrophotometrically by the use of a chro-
mogenic substrate S-225 I. Supernatants were incubated with plasmin to
determine total u-PA activity. No glomerular fibrin deposits were
detected by immunofluorescent technique on renal biopsies.
Results:
means SEM
Sham
(N = 6) P
CsAR
(N = 6)
P-creatinine p.mol/ 34.2 3.4 NS 40.7 3.5
liter
GPCA units of ill 13 NS 114±20
tissue factor/mg
glom. prot
GFA gfibrin 3.25 0.24 <0.005 4.25 0.15
lyzed/mg glom.
prot.
u-PA activity U/mg 3.8 0.5 <0.005 6.8 0.6
glom. prot.
Total u-PA activity 8.2 0.7 <0.025 12.5 1.6
U/mg glom. prot.
We conclude that I) a short course of acute CsA intoxication in SD rats
does not modify GPCA and enhances GFA. 2) This increase in GFA is
mediated by enhancement of u-PA and probably also t-PA activities
(SDS-PAGE zymography not shown). 3) By promoting glomerular
fibrinolysis, CsA might possibly protect the SD rat from glomerular
thromboses encountered in other animal models using high doses of this
drug. Such changes need to be explored in human glomeruli.
Antihypertensive therapy with the long-acting angiotensin-converting
enzyme inhibitor lisinopril in patients with renal impairment. C. Fiklocki,
G. Keusch, Nephrologische Station, Departement für Innere Medizin,
Universitatsspital, 8091 Zurich, Switzerland. The antihypertensive ef-
ficacy and safety of the new long-acting nonsulfisydryl angiotensin-
converting enzyme inhibitor, lisinopril, were assessed in 18 patients
(aged 23-50 years) with hypertension associated with impaired renal
function (creatinine clearance 10 to 30 mI/mm) in an open study of 12
weeks duration. After discontinuation of all previous antihypertensive
drugs except furosemide for 2 to 23 days, lisinopril was given initially 5
mg daily in patients with creatinine clearance of less than 30 mI/mm and
10 mg in all others. According to the blood pressure response the dose
was titrated to a maximum of 40 mg daily.
Baseline Week 12
Systolic blood pressure 155 26 122 21
mm Hg
Diastolic blood pressure 106 7 80 l0
mm Hg
Creatinine clearance 33 16 36 19
mI/mm
Protein excretion 1.80 1.90 1.57 2.50k'
g/24 hrs
Serum potassium 4.13 0.50 4.30 0.50
mmol/liter
Hemoglobin g/dl 11.80 2.20 10.40 2.lOa
Results (mean I SD; significance: a P < 0.01; b P< 0.05, Wilcoxon
test for paired data)
Serum concentrations of lisinopril varied individually and correlated
significantly with serum creatinine concentrations (r = 0.81; P <0.001).
Mild adverse drug effects were reported on 10 occasions but no patient
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required discontinuation of therapy. We conclude that lisinopril is a
powerful blood pressure lowering agent; kidney function was stable and
serum potassium levels maintained. The antiproteinuric effect known
from other ACE-inhibitors seems to reflect a decrease in transglomer-
ular capillary pressure.
Spontaneous rupture of the kidney. W. Probst, U. Binswanger,
Nephrologische Station, Dept. für Innere Medizin, Universitatsspilal,
Zurich, Switzerland. Spontaneous rupture of the kidney and perineph-
nc hematoma is a rare complication of different diseases. In 1896
Kuster found ten cases in a review of 30,000 autopsies. After this review
several reports, most limited to specific etiologies, have appeared in the
literature. This report describes three cases of nontraumatic bleeding from
the kidney as a complication of three different diseases.
Pat. 1 (F.H.) Pat. 2 (H.B.) Pat, 3 (W.G.)
Age years 67 62 62
Primary disease
Additional
Periarteritis
nodosa
Renal vasculitis
Interstitial
nephropathy
Urothelial
Interstitial
nephropathy
Anticoagulatio&'
problem carcinoma
Renal rep!. — Hemodia!, CAPD since
therapya before
transpl.
3 years
Renal — 9 years ago —
transplantation
Main diagn. Computed Computed Computed
procedure tomography tomography tomography
Treatment Nephrectomy +
Immunosup-
pression
Nephrectomy +
ureterectomy
Nephrectomy
a Before rupture of the kidney b Because of mitral valve replace-
ment
Although uncommon, there are multiple causes of nontraumatic bleed-
ing from the kidney. The most common etiologies are renal tumors,
vascular malformations, renal infarction, renal vasculitis and anticoag-
ulation. During the last years several cases were described with
occurrence of spontaneous renal hematoma in patients with acquired
cystic disease of the kidney undergoing chronic hemodialysis. In patient
3 the radiologic and histologic examination revealed the occurrence of
multiple acquired renal cysts. The etiology of an acute renal failure of
unknown origin was cleared in patient 1 by the histologic examination
of the nephrectomy specimen. In patient 2 the renal hemorrhage was
the first sign of the urothelial carcinoma. In summary, we have
presented three unusual cases of spontaneous renal rupture, which all
revealed a previously unknown diagnosis.
Asymptomatic microhematurla of unknown etiology: Follow-up in 28
patients. S. Ruttimann, M. Dreifuss, A. di Gallo, B. Huser, U.C.
Dubach, Medizinische Universitatspolik!inik und Abteilung für Neph-
rologie, Departement für innere Medizin, CH-4031 Kantonsspital
Base!, Base!, Switzerland. The etiology of asymptomatic microhema-
turia (AM) discovered by routine urinalysis often remains unknown
despite extensive work-up. The clinical significance of AM of unknown
origin is not well understood. There are only few follow-up studies
published addressing its long-term outcome. We followed 28 patients
with AM of unknown etiology over a mean period of 3.7 years (2.6 to
5.3). The urine was examined by the dipstick method. A urine sediment
was prepared by standard techniques. Erythrocyturia was judged as
grade I or grade 11(3-9 or >9 erythrocytes/hpf) and classified by
phase-contrast microscopy as glomerular or non-glomerular (>30% or
<30% of erythrocytes with glomerular characteristics). Results. All
patients were in good health during the whole follow-up. None devel-
opped significant proteinunia or gross hematuria. AM persisted in 22
patients (79%). Persistence of AM was independent of grade and
morphology of the AM. The 15 patients who initially showed grade I
AM had grade I AM in 92% and grade II AM in 8% of their follow-up
urine analyses. The 7 patients with grade II AM at the first examination
had grade II AM in 65% and grade I AM in 35% of follow-up urine
analyses (P = 0.007). The last morphological classification of AM
corresponded to the first in all patients with persistent grade II AM, but
only in 80% of patients with grade I AM. Conclusions. I) Most of the
AM of unknown etiology persist over several years and are independent
of grade and morphology of erythrocyturia. Since patients with persist-
ent AM remained asymptomatic over a mean of 3.7 years, repeated
extensive diagnostic work-up after a careful initial evaluation is not
indicated. 2) Most patients show a fairly constant grade of AM, but a
grade II AM seems to be more variable than grade I AM. 3) In grade I
AM the morphological classification is less reliable and therefore of
limited value; in grade II AM, its clinical significance is unquestioned.
Salt retention in experimental nephrotlc syndrome: Its independence of
hormonal regulation. B. Vogt, H. Favre, Division de Nephrologie,
Hôpital Cantonal Universitaire de Genève, Genève, Switzerland. Ne-
phrotic syndrome (NS) is associated with avid salt retention. We have
previously shown using a rat model of puromycin (PA) induced NS that
Na-K-ATPase activity is increased in the cortical collecting tubule
(CCT). The regulatory role of aldosterone and endogenous digitalis-like
factor (EDLF), both hormones known to act on CCT, was investigated
in the present study. NS was induced in male WISTAR rats with one
single injection of PA (15 mg/lOO g i.p.). At day eight the animals were
anesthetized, left kidney microdissected and the activity of Na-K-
ATPase measured in single nephron segments. The right kidney was
removed, EDLF extracted and measured by a receptor binding assay.
Results: Na-K-ATPase activity (pmol/mm/hr SE): control vs. NS:
Group A: 3 m sodium intake/day: cortical ascending limb (CAL): 5206
476 vs. 5236 418 (P = 1.000), CCT 1065 68 vs. 2081 274(P =
0.036); Group B: 0.06 m sodium intake/day: CAL 5458 397 vs. 4592
231 (P=0.1422),CCT 1544± 105 vs. 2840± 117 (P=0.036). Group
C: Adrenalectomy (ADX): CAL 4455 376 vs. 3751 307 (P =
0.0935); CCT 459 71 vs. 1224 103 (P = 0.036). EDLF (nmol/mg
SD): control vs. NS: Group A: 1.566 1.14 vs. 1.986 0.64 (P = 0.144).
Group B: 0.967 0.67 vs. 1.210 0.35 (P = 0.082). Group C: 0.742
0.20 vs. 1.459 0.71 (P = 0.036). Na-K-ATPase activity in the CCT
from PA induced NS rats is increased twofold in all three groups. This
relationship is not modified by ADX. EDLF correlates with extracel-
lular fluid volume but has no influence on Na-K-ATPase activity in the
CCT from nephrotic animals. These findings favor the hypothesis of
intrinsic renal mechanisms as responsible for salt retention in NS.
Is the human growth-hormone (HGH) induced rise in GFR blunted by
angiotensln Il-converting enzyme inhibitors? D. Haffner, J.B. Rosman,
0. Mehis, E. Ritz, Med. Univ. Klinik of Heidelberg, Heidelberg, FRG,
and Med. Univ. Poliklinik, Bern, Switzerland. HGH is known to cause
a reversible rise in glomerular filtration rate (GFR), mediated by a still
unknown factor. This could be proven in healthy subjects and is
observed in HGH treated dwarfs who had a pathologically low GFR
before institution of OH therapy. Unknown is whether the now avail-
able recombinant HGH (rHGH) causes the same response and if the
GFR increase is All dependent, as seems to be the case in hyperfiltening
diabetic patients. We investigated 8 healthy subjects who injected
themselves for two consecutive periods of three days with 4 units of
rHGH twice daily, and four inulin clearances were performed: BL (day
I), OH (day 5: after 3 days of rHGH treatment), E (day 11: after 5 days
washout and I day pretreatment with 20mg enalapril daily) and E + GH
(day 15: after 3 days of rHGH treatment combined with 20 mg enalapril
daily). Serum ACE was measured and was under enalapril below 5% of
the values on the BL day. Clearance and relevant laboratory data
(medians) were as follows:
BL P OH E P E+GH
Inulin-cI 114 <0.05 135 III <0.05 131
mi/mm
IGF-1 ng/rnI 185 <0.05 535 251 <0.05 619
IGF-2 ng/rnl 606 — 564 654 — 590
IGF-BP 2745 — 3692 3117 <0.05 4272
ng/ml
c-peptide 1.05 — 1.55 1.50 — 2.25
mg/rn!
Glucagon 306 — 210 295 — 295
pg/mi
S-phosphate 1.05 — 1.10 1.15 — 1.10
rnrnol/liter
S-urea 28 <0.05 18 26 — 19
mmol/liter
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We conclude that: 1) rHGH increases GFR to the same extent as
pituitary-derived HGH, and 2) the increase in GFR is not blunted by
ACE inhibition, that is, is not All dependent.
Interleukin 1: A new factor influencing by different mechanisms the
tubular reabsorption of sodium and calcium. J. Caverzasio, f.M. Dayer,
R. Rizzoli, f-P. Bonjour Div. C/in. Physiopathologie, Dept de Médi-
cine, Université de Genève, Genève, Switzerland. Recent data from this
laboratory indicate that acute administration of recombinant human
interleukin-1/3 (IL-l/3) in rats induces a transient natriuresis with
increased water excretion but no change in Ca and P, metabolism
(Caverzasio et a!, 1988). This observation strongly suggests that IL-I
could be the key mediator in endotoxin-induced natriuresis. Chronic
administration of IL-i in mice was shown to induce an elevation of
plasma calcium ([Ca]1). This effect was thought to result mainly from
increased bone resorption since IL-i is a potent, in vitro bone-
resorptive agent. In the present study, the chronic effect of IL-I /3 on Ca
metabolism was evaluated in TPTX rats. Subcutaneous injection of
IL-l/3 (1-1.5 gIday) induced a significant elevation in [Ca]1 (z[Ca}:
0.15 -0.34mM). This elevation in [Ca]1 was associated with a decreased
fasting urinary Ca excretion per ml glomerular filtration rate (U/ml
GFR). The change in the tubular transport capacity of Ca was assessed
under acute Ca gluconate infusion. The index of the tubular reabsorp-
tion of Ca (TRCaI) was significantly increased by IL 1-/3 as compared to
vehicle treated rats (2.18 0.14, N = 6, vs. 1.79 0.07 mmol/liter
GFR, N = 6, P < 0.05). The increased TRCaI with IL-l/3 was not
associated with any change in tubular reabsorption of sodium and
clearance of inulin. The ionized/total [Ca]1 ratio was not different
between the two experimental groups (LL-l/3: 39.5 1.6 and veh: 37
1. 1%) The elevation in [Ca]1 was associated with a decreased plasma P
(IL-l/3: 3.37 0.21, N = 6 and veh: 4.12 0.28, mi, N = 6, P <0.01)
but no change in plasma magnesium, blood pH, pCO2, or bicarbonate
concentration. In TPTX rats treated with IL-l/3, the urinary excretion
of cAMP was identical to that of control animal. In conclusion, the
results of this study indicate that chronic administration of IL-1/3 in
TPTX rats enhanced fasting [Ca}1 and decreased plasma P. The
elevation in calcemia was associated with a decreased fasting calciuria
indicating that under these experimental conditions, the hypercalcemic
effect of IL-I /3 was mainly due to a stimulation in Ca reabsorption. The
IL-I/3 effect on tubular Ca transport was not associated with changes in
Na reabsorption, cAMP excretion or in acid-base balance. These data
strongly suggest that change in the tubular handling of calcium could
contribute to interleukin-l induced hypercalcemia in experimental
animals. Since some solid tumors have been shown to express inter-
leukin-l, the question arises whether this cytokine could contribute to
the increase tubular reabsorption of Ca in hypercalcemic cancer pa-
tients.
Final height of children treated for ESRF in Switzerland since 1970. E.
Leumann, F. Egli, J.P. Guignard, 0. Oetliker, L. Paunier, Universi-
täts-Kinderklinik Zurich, Switzerland. Final height of patients with
chronic renal failure (CRF) treated with dialysis/transplantation before
age 15 yrs is usually diminished; however, data are contradictory. To
eliminate patient selection, final height was analyzed in all patients
followed up in a prospective study on CRF in children in Switzerland.
Six of 35 patients were excluded because of metabolic disease (5) or
missing data. Final height was defined as age >21 yrs with growth arrest
>3 years. All patients had received at least one cadaver transplant with
prednisone and azathioprine as immunosuppression. Results. Average
final height was 160.8 cm (—2.47 standard dcv. scores, SDS) in 16 males
and 152.8 cm (—2.00 SDS) in 13 females. The 18 patients with
uropathy/hypodysplasia were considerably smaller (average —2.71
SDS) than the 11 remaining patients (— 1.52 SDS). Further analysis in 23
patients disclosed 3 different growth patterns: group A) continuing
height loss before age 16 yrs (N = 12); group B) constant height deficit
after age 10 (3), and group C) improved growth (8). Adult height in male
patients was considerably better in group C (167.9 cm) than A (153.8
cm). Improved growth was seen in 7 of 9 patients with good graft
function, but only exceptionally in those with poor graft function.
Conclusions. Final height was nearly always diminished, although
rarely below —3.5 SDS. Results may improve with better management
before ESRD, earlier (re)transplantation, and administration of cyclos-
porine and growth hormone.
Transient impairment of renal function after high.dose intravenous IgG
treatment in patients with kidney diseases. J.A. Schfferli, M. Leski, H.
Favre, P. Imbach, U. Nydegger, K. Davies, Division de Néphrologie,
Hôpital Can tonal Universitaire, Genéve; Zentrallaboratorium des
Blutspendedienstes SRK and Hamatologisches Zentrallabor, Inseispi-
tal, Bern, Switzerland; and Department of Medicine, R.P.M.S., Ham-
mersmirh Hospital, London, United Kingdom. In a open trial of high
dose intravenous (i.v.) IgG therapy in nephrotic patients with glomer-
ulonephritis, the first six patients demonstrated a transient rise in
plasma creatinine while receiving lgG (0.4 glkg/day for 5 days). The
highest rise was observed in a patient with impaired renal function:
pre-treatment creatinine 293 smol/liter, post-infusion: 650 mol/liter,
and 2 weeks later: 295 ttmol/Iiter. Clearance studies were performed
before and immediately after treatment in three of these patients who
received two series of infusions. The increase in plasma creatinine was
attributable exclusively to a modification in tubular transport of creat-
mine in two of these patients, while in the third, a fall in glomerular
filtration rate was also observed. Two other patients (with pre-existing
renal impairment, but without nephrotic syndrome) are also described,
in whom a transient and reversible rise in plasma creatinine occurred
directly following i.v. lgG therapy for idiopathic thrombocytopenic
purpura, and acquired factor VIII deficiency, respectively. The latter
one became transiently oliguric. These observations suggest that high
dose i.v. lgG infusion can produce short-lived perturbations in renal
function in patients with heavy proteinuria or pre-existing renal impair-
ment.
Acute tubulo.interstitial nephritis with uveitis in two HLA-identical
siblings. M. Hugentobler, G. Keusch, D. Frei, U. Binswanger, Neph-
rologische Station, Departement fur Innere Medizin, Universitatsspi-
tal, 8091 Zurich, Switzerland. Since the first description fifteen years
ago, the syndrome of acute tubulo-interstitial nephritis with uveitis
(TINU) has become a well defined disease showing an unique coinci-
dence of renal impairment and ocular inflammation. We describe two
HLA-identical female siblings of 46 and 43 years of age presenting with
this syndrome. One of the two sisters was admitted to the hospital with
acute renal failure (peak serum creatinine level 773 mol/liter) without
ocular involvement. Kidney biopsy revealed acute interstitial nephritis
with severe mononuclear cell infiltration. Resolving under a treatment
with corticosteroids, the patient showed an acute uveitis two months
after withdrawal of this medication. The other patient initially suffered
from an acute uveitis which disappeared under local steroid therapy.
Renal biopsy showing the same aspect of acute tubulo-interstitial
nephritis as her sister's was taken after one month of general malaise
with fever and weight loss, Renal function was slightly impaired (peak
serum creatinine level 126 mol/liter) and responded well to steroids.
As we did not find any obvious infection, drug ingestion or association
with other immune disease, idiopathic development was assumed as it
is by most case reports published hitherto. Both sisters not only showed
the same TINU-syndrome proven by renal biopsy, but also turned out
to have a total HLA (HLA-AIB/C, HLA-DR) identity. Though the
etiology is unknown, our observation of the TINU-syndrome in two
HLA-identical siblings points towards the question of a genetic defect
in this immunological disorder.
Analgesic nephropathy: Acceptance rate to renal replacement therapy
in Switzerland, 1975—1987. M.C. Hugentobler, F.P. Brunner, Medizini-
sche Klinik, Kantonsspital, CH-8500 Frauenfeld, Medizinische Univer-
sitätsklinik, Kantonsspital, CH-4031 Basel, Switzerland. Analgesic
nephropathy (AN) was first described in Switzerland in 1953 and has
persisted as one of the most common causes of ESRF in Swiss patients
accepted for RRT, with 18% in 1987. Using the data base of the EDTA
Registry, which contains records of about 90% of all Swiss patients on
RRT, we calculated the age- and sex-specific acceptance rates to RRT
for AN in 1975—1987. The overall acceptance rate rose from 7.3 patients
per million population (pmp) in 1975 to 13.4 pmp in 1980, and tended to
decrease slowly thereafter to reach 10.5 pmp in 1987. The overall
acceptance rate for females peaked at 20 pmp in 1980 and fell to 15 pmp
in 1987. The decrease in the acceptance rate since 1980 occurred in spite
of stable or increasing age specific acceptance rates in the 10 year age
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cohorts between 55 and 85. In the largest 10 year cohort, that is, ages 55
to 64, the acceptance rate continued to increase from 22 pmp aged 55 to
64 in 1980 to 47 pmp in 1987. In contrast, the acceptance rate decreased
from 39 pmp (age 45-54) and 7 pmp (age 35-44) in 1980 to 8 pmp (age
45-54) and 2 pmp (age 35-44) in 1987. This marked decrease in the
acceptance rate of patients below age 55 probably reflects a change in
the epidemiology of analgesic abuse in young adults between 1960 and
1980 rather than being a consequence of the decision, in effect since
1982, to restrict the sale of phenacetin containing analgesics to prescrip-
tion only, and removal of phenacetin from the majority of mixed
analgesic preparations by the drug companies in recent years.
Cutaneous gangrene with hyperparathyroidism in patients on hemodi-
alysis. H. Jungbluth, K. Zdruba, Nierenstation, Stadtspital Waid
Zurich, Zurich, Switzerland. Cutaneous gangrene is a rare but recog-
nized complication in renal failure with hyperparathyroidism. The
mechanisms responsible for the development of the lesions are poorly
understood. We describe two women, aged 67 and 69 years, who were
on thrice-weekly maintenance hemodialysis because of chronic renal
failure since 5 and 6 years, respectively. Both patients developed
painful necrosis of the skin of the lower extremities. The ulcerations did
not respond to treatment with local measures but progressed rapidly by
lateral extension and central necrosis. Skin biopsies showed necrosis
and inflammation of the epidermis and dermis, but calcification of the
soft tissue vessels could not be demonstrated. The diagnosis of second-
ary hyperparathyroidism was made. Parathormone levels (N-assay,
hPTH 1-84) were greatly elevated at 1100 and > 2000 pglml (normal
range < 250 pg/mI), respectively. Serum calcium was within the normal
range (2.45 and 2.25 mmol/liter, respectively), and phosphorus was
slightly elevated (1.9 and 2.44 mmol/liter, respectively). The association
between hyperparathyroidism and the skin lesion was considered, and
subtotal parathyroidectomy was done, Histological findings were chief
cell hyperplasia in all of the removed glands. The postoperative course
was uneventful, and the extensive skin lesions began to heal slowly.
The healing time was 10 and 4 months, respectively. It is concluded that
hyperparathyroidism in end-stage renal disease was responsible for the
development of cutaneous gangrene; the mechanisms remain unknown.
In the case of cutaneous gangrene the possibility of hyperparathyroid-
ism should be taken in consideration. Subtotal parathyroidectomy is
then indicated in this life threatening complication.
Efficacy of subcutaneous application of erythropoietin in patients on
maintenance hemodialysis. H. Jun gbluth, K. Zaruba, Nierenstation,
Stadtspital Waid Zurich, Zurich, Switzerland. Recombinant human
erythropoietin (EPO) is well established in correcting anemia of end-
stage renal disease by i.v. application of the hormone. EPO is now
recommended for subcutaneous (s.c.) application, too. We studied 7
patients on maintenance hemodialysis, who were previously treated
with EPO three times a week i.v., receiving doses from 45 up to ISO
(mean 72) lU/kg body weight. On the whole, patients needed 12085 LU
(range 6300 to 21600 LU) per week. The hemoglobin concentration was
in a steady state in all patients at a mean level of 10.2 g%. Patients were
then switched to a subcutaneous application schedule. All but one were
treated by a twice weekly regimen. In the follow-up period (3 months)
the dose of EPO was adjusted, in order to prevent hemoglobin from
increasing. Finally the single dose of EPO ranged from 25 to 150 (mean
56) LU/kg body weight. The weekly dose was only 6385 IU (range 3600
to 13600 IU), and the mean hemoglobin concentration (10.3 g%) had not
changed. Regarding the weekly dose of EPO, there was a remarkable
nearly 50% reduction in the consumption of EPO, which fell from 12085
to 6385 IU. Thus, twice weekly subcutaneous application of EPO
provides a most effective, well tolerated, and cost sparing treatment.
Comparison of prophylactic filling of central venous hemodialysis
catheters with heparin or urokinase. H. Freudiger, Z. Glück, K. Meyer,
Abteilung für Nephrologie, Regionalspital, 2502 Biel, Switzerland. We
assessed the efficacy and safety of prophylactic filling of central venous
hemodialysis catheters with either heparin (5000 lU/mI) or heparin
combined with urokinase (2500 LU/mI). Twenty-five consecutive pa-
tients were randomly assigned to receive either heparin alone after each
dialysis (11 pts) or urokinase in addition to heparin after every other
dialysis (14 pts). The total observation time was 475 days (43 8
days/pt; mean SEM) for the heparin group and 801 days (57 Il
days/pt) for the urokinase group (P = 0.35). There was 1 catheter failure
due to kinking (urokinase group). In each group I catheter had to be
removed for staphylococcus septicemia and in both groups I throm-
botic occlusion occurred, which was easily dissolved with urokinase. In
the urokinase group there was I bleeding from an insertion site which
required transfusions. A retinal bleeding occurred in a diabetic patient
one day after filling of the catheter with urokinase and 1 patient with
acute renal failure suffered from an upper g-i bleeding 2 days after
urokinase application. Blood flow was above 250 mI/mm in all catheters
and coagulation parameters remained within normal limits in all pa-
tients. Conclusion. Prophylactic filling of hemodialysis catheters with
heparin and urokinase did not prove to be superior to heparin alone,
which was safe and effective in preventing thrombotic catheter occlu-
sion. Thrombosed catheters, however, could easily be reopened with
urokinase.
Low molecular weight heparin during hemofiltration. D. Kiss, D.
Pless, Dialysestation, Dep. of Medicine, Kantonsspital, CH-4410 Lies-
tal, Switzerland. To compare the effect of low molecular weight heparin
(Fragmin) versus heparin (Liquemin) on ultrafiltration (UF) rate and
bleeding time, we studied 5 patients during 88 hemoflltrations over 8
consecutive weeks. The UF-rate was measured 15 minutes after the
beginning and at the end of the treatment with a calibrated glass and a
stopwatch. At the end of treatment the bleeding time out of the
puncture sites (arterial and venous) was measured with a stopwatch.
The dose of heparin was 50 U/kg initially followed by 1000 U/h as
infusion. The dose of low molecular weight heparin was 50 U/kg given
as bolus at the start of hemofiltration. Every other week the anticoag-
ulant was changed. The blood flow rate was set at 400 mI/mm. The
membrane used was a polysulfone capillary dialyzer (HF-80). The
hemofiltration was performed with 22.5 liters in all patients. The
intraindividual comparison of the UF-rate was not significantly different
at the beginning and the end of treatment. The mean (± Sn) UF-rate at
the start was 156.6 13.6 mI/mm with heparin and 160.2 20.0 mI/mm
with low molecular weight heparin. At the end of treatment the UF-rate
was 133.9 16.0 mI/mm with heparin vs. 133.0 13.8 mI/mm. The
bleeding time of the 5 patients from the arterial puncture site was 14.7
7.8 mm with heparin and 12.3 4.3 mm with low molecular weight
heparin (P < 0.05). The bleeding time from the venous puncture site
was 13.1 6.2 mm vs. 11.5 3.4 mm (P < 0.1). No side effects were
observed. The study approach used is an easy and useful test of
anticoagulation during hemofiltration. The intraindividual comparison
of the U F-rate was comparable in the beginning and at the end of
treatment. The bleeding time from the puncture sites at the end of
treatment seems to be shorter with low molecular weight heparin. The
single dose treatment with low molecular weight heparin during hemo-
filtration is easier and seems to be superior to the widely used continous
heparin treatment.
Verification of sodium modelling computation by sodium measure-
ments. A. Edward, J.A. Cerutti, B. Reinhardt, Ospedale Civico,
Lugano, Switzerland, and Oberursel, Federal Republic of Germany.
Intradialytic morbidity is common during conventional hemodialysis.
This phenomenon can be attributed in part to an inadequate water and
sodium removal which produces osmotic imbalance and hypovolemia.
The aim of each dialytic treatment is to remove that amount of sodium
and water which has been taken up by the patient in the dialysis-free
interval. It is easy to monitor the fluid removal, but not the sodium
removal. To determine the sodium removal, the mix of dialysate and
ultrafiltrate has to be collected and sodium concentration has to be
correctly measured, particularly in small concentration differences
between the mix and the fresh dialysis fluid. It is impossible to manage
this necessary procedure of determination of sodium removal during
each routine dialysis. To solve this problem, different authors like
Gotch, Kimura, Stiller and Mann, and others developed a mathematical
model to calculate the sodium removal instead of measuring. But the
clinical application of sodium modelling is depending on the correct
correlation between the results of the computation and the reality in the
patient. To investigate this correlation, we measured the kinetics and
the total amount of sodium removal and plasma sodium concentration
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and compared these measured values with the calculated values of
sodium modelling computation of a commercially available computer,
the CMS 08 of Fresenius. Sixty open circuit hemodialysis sessions of
4-5 hours duration were carried out in 9 patients. Sodium concentra-
tions were measured by flame photometer. For quantitative determina-
tion of the sodium removal the ultrafiltrate and dialysate were collected
every hour and weighed, and the sodium content was measured, so also
with the total volume for control. Hence it followed that there was an
average deviation of 6% between the measured and calculated total
sodium removal. The difference between the calculated and measured
plasma sodium concentration (kinetics and total amount) was in the
range of I mmol/liter. Due to these good agreements of calculated and
measured values the sodium modelling computation is believed to be
suitable as an information and therapy creation system.
Glucose intolerance and prolonged renal transplant insufficiency due to
ketokonazole-cyclosporin A interaction. D. Kiss, G. Thie!, Dep. of
Medicine, Kantonsspita!, CH-4410 Liestal and Dep. of Nephrology,
CH-4000 Base!, Switzer!and. The rise of cyclosporine concentration in
patients under ketokonazole treatment was repeatedly reported and has
been interpreted as ketokonazole-induced inhibition of hepatic metab-
olism. Our patient was a 26 years old woman who received a cadaver
kidney transplant 38 months ago with a stable graft function on a
cyclosporin A monotherapy. Due to chronic candida vaginitis she
additionally received ketokonazole (400 mg/day). After 12 hours after
the second dose of ketokonazole she suffered from headache, vomiting
and tremor. The investigations 48 hours after the first dose of ketokon-
azole revealed an increased blood pressure, a rise of serum creatinine
from 110 to 274 mol/liter, increased liver enzymes and an increased
fasting blood-glucose (11.8 mmol/liter). The cyclosporin A trough level
was 1300 nglml (polyclonal radioimmunoassay). The determination of
the cyclosporin A parent drug level was elevated to 1540 pg/liter. Due
to the clinical symptoms and the laboratory findings, the diagnosis of
acute cyclosporin A toxicity induced by ketokonazole was made. The
acute cyclosporin A toxicity led to a long-lasting impairment of renal
function and glucose tolerance. The known inhibition of the cyclosporin
A hepatic metabolism by ketokonazole is demonstrated by an impres-
sive rise of the parent drug level. Since the glucose intolerance has so
far not been reported, the increased glucose levels could have been the
expression of cyclosporin A toxicity. The explanation for the impaired
glucose tolerance is not known, but might be due to peripheral insulin
resistance and not to deficient insulin secretion. Our results may
indicate that the high level of the parent drug induced by the inhibition
of the hepatic metabolism by ketokonazole is the main factor inducing
nephrotoxicity and glucose intolerance. Due to the long duration (4
weeks) of toxic effects, care is indicated when using ketokonazole in
patients treated with cyclosporin A.
Immunologic monitoring of steroid withdrawal in renal allograft recip-
ients on triple therapy with cyclosporin A, azathioprine and prednisone.
A. v. Kiparski, D. Frei, W. Fierz, G. Uh!schmid, F. Largiader, U.
Binswanger, Nephrologische Station, Departement für Innere Medizin
und Departement für Chirurgie, Universitatsspital, 8091 Zurich, Swit-
zerland. The lymphocyte subsets in the periperal blood were examined
in 35 stable renal allograft recipients on maintenance triple therapy with
cyclosporin A (CsA), azathioprine (Aza) and prednisone (Pred). In 20/
35 recipients Pred was discontinued. Pred withdrawal was successful in
12 (60%) patients (group A) and unsuccessful in 8 (40%) patients (group
B). Group B had a significantly higher CD4/CD8 ratio before withdrawal
of Pred than group A (2.4 1.4 vs. 1.4 0.6; P < 0.05) although only
4/8 patients had a high ratio (> 2.5). After cessation of Pred. Leu3
(helper/inducer) and Leu2 (suppressor/cytotoxic) cells increased in
group B and Leu3 cells were significantly higher than in group A (P <
0.02). The Leu2/Leu15 (cytotoxic) subset was responsible for the
significant increase of the Leu2 cells (P < 0.05). However, in 6/12
recipients of group A there was also an increase of Leu3 and Leu2
cells but a decrease of these subsets in the other 6 patients. After
withdrawal of Pred group A was compared to the 15 patients with triple
therapy who were not withdrawn, 15 patients with conventional therapy
(Aza and Pred) and 15 blood donors. B-cells (Leul2) and Leull
NK-cells were significantly lower in the transplanted patients compared
to the blood donors. Group A and the conventionally treated patients
had significantly decreased helper/inducer cells (Leu3) with a signifi-
cantly lower CD4/CD8 ratio than the controls. In the transplant group a
reversal of the Leu3 subsets was observed resulting in higher T-helper
cell values (Leu3/Leu8) and significantly lower T-suppressor-inducer
cell counts (Leu3/Leu8) compared to the controls. A similar distri-
bution was seen already pretransplant in 14 uremic patients. In conclu-
sion, patients with a high CD4/CD8 ratio might represent a risk group
for Pred withdrawal failure, although the outcome could not be pre-
dicted in the individual patient.
Urine cytology—a useful tool for the diagnosis of rejection and cyclos-
porine toxicity. M. Kyo, F. Gudat, P. Daiquen, B. Huser, M.J.
Mihatsch, G. Thiel, Institut für Pathologie der Universilät Base!,
Abtei!ung für Nephro!ogie, Kantonsspita! Base!, Basel, Switzerland.
More than 700 urine samples of 37 renal transplants were studied to
develop a routine method for the diagnosis of rejection (RX) and
cyclosporine toxicity. Freshly voided second morning urine samples
were collected every second day after transplantation until discharge
and at each consultation up to day 60. After cell count and differenti-
ation in Papanicolaou-stain, cytospin preparations were made for
immunocytochemistry with APAPP-method. Cell Count was made for
reacting cells with the following monoclonal antibodies: CD2 (pan T
cell), CD4 (helper/inducer T cell), CD8 (suppressor/cytotoxic T cell),
CD25 (interleukin 2 receptor), HLA-DR (HLA class II antigen), Lu-5
(pankeratin). Conclusions: I.) Patients with rejection, cyclosporine
toxicity or other complications have more than 2 x 10 cells/mI in urine.
Patients with cyclosporine toxicity in early stages excrete predomi-
nantly proximal tubular cells. 2.) CD25 positive cells have the highest
sensitivity, specificity and predictive value for the diagnosis of RX.
CD8 positive cells and the ratio of HLA-DRJLu-5 positive cells are
helpful in the diagnosis of rejection.
Combined liver and kidney transplantation in primary hyperoxaluria
type I (PH I). E. Leumann, Universitäts-Kinderk!inik Zurich, Zurich,
Switzerland. Deficiency of the hepatic peroxisomal enzyme alanine:
glyoxylate aminotransferase (AGT) in PH I results in nephrolithiasis
and renal failure. A 14-year-old boy presented with severe renal failure
(serum creatinine 2700 mol/liter) and nephrocalcinosis. Diagnosis of
PH 1 was suggested from similar findings in his younger brother and was
proven by deficient AGT (0.04 instead of 2.7 - 8.4, Dr. C. Danpure,
Harrow) in liver biopsy. Combined transplantation was performed in
Cambridge (Prof. R. Caine) after intensive hemodialysis during 7
months. The further course was uneventful except for slight initial liver
rejection, Urinary excretion of glycolate was normal (130 mmol/mol
creatinine, normal <200). In contrast, urinary oxalate excretion was
considerably elevated at 2 months (250 mmol/mol creatinine, normal
<80), and this ratio was still elevated at 7 months (110 mmol/mol
creatinine) as a result of the increased oxalate pool. Enzyme replace-
ment by liver transplantation represents a causal therapy in pyridoxin-
resistant PH I. The best timing (that is, isolated liver transplantation
before renal failure or combined transplantation after renal failure) is
debated.
Bone mineral density of lumbar spine, lemoral neck, and distal tibia in
dialysis and kidney transplanted patients. J.P. Casez, H. Saxenhofer, C.
Descoeudres, A. Montandon, Ph. Jaeger, Medizinische Universi-
tatspoliklinik, Inselspital, 3010 Bern, Switzerland. Bone mineral density
(BMD) was measured with X-ray densitometry (Hologic QDR 1000) in
70 dialysis (37 men, 33 women) and 122 kidney transplanted patients (50
men, 72 women) in a cross sectional study. Lumbar spine (mostly
spongious bone) femoral neck (mostly cortical bone), tibia shaft (corti-
cal), tibia metaphysa (spongious) and tibia epiphysa (spongious) were
examined. Tibia was scanned from the ankle using a soft tissue
compensator device (Casez 1989, VIItn International Workshop on
Bone Densitometry). BMD results, expressed as Z-score (SD from mean
BMD of age and sex matched controls from Berne) are displayed in
table ( 5EM) and statistics are performed with one way ANOVA.
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Lumbar sp. Fern. neck Tib. shaft
Dialysis men —0.85 0.2 —0.71 0.3k —2.5 0.6
Dialysis women 0.16 0.2" —0.74 0.2 —1.03 0.4
Men vs. women, P = 0.01 NS NS
Transpl. men —1.3 0.2a —1.16 0.2a —2.1 0.5
Transpl. women —0.8 0.14a —1.17 0.la —1.5 0.2
Men vs. women, P 0.54 NS NS
Tib.
metaph, Tib. epiph.
Dialysis men —2.7 0.6a —1.4 0.5
Dialysis women —1.3 0.4a —0.7 03b
Men vs. women, P = 0,05 NS
Transpi. men
Transpl. women
—3.2 0.4a
—1.8 0.2
—1.9 0.4
—1.5 0.2
Men vs. women, P <0.001 NS
a Signif vs. control b Signif vs. transplanted patients
Comments: at most sites, BMD was reduced in patients vs. control and
in men vs. women. Lower BMD observed in transplanted vs. dialysis
patients may be related to immunosuppressive therapy. Lumbar spine
seems to be the least affected site probably due toartefacts induced by
aortal calcifications and/or vertebral deformations. Significantly lower
BMD at metaphysal distal tibia (P < 0.01) than at any other site
demonstrates the particularly high sensitivity of this artefact-free area
for detection of early bone loss.
Influence of rejection episodes and immunosuppressive therapy on the
lymphocyte subsets of patients after renal transplantation. A. v. Kiparski,
D. Frei, W. Fierz, G. Uhlschmid, F. Largiader, U. Binswanger,
Nephro!ogische Station, Departement für Innere Medizin und Depar-
tement für Chirurgie, Universitatssspital, 8091 Zurich, Switzerland.
The lymphocyte subsets in the peripheral blood were examined 3 times
a week in 17 patients receiving a cadaveric renal allograft, using 2-color
flow cytometry and several combinations of monoclonal antibodies.
Patients who experienced a rejection crisis (N = 12) had a significantly
higher CD4/CD8 ratio (2.72 1.26 mean SD) than patients with stable
graft function (1.76 1.33, P <0.05). Nine/12 patients showed 0-3 days
prior to the rejection episode an increase of the CD4/CD8 ratio ( 0.5)
and/or a high ratio ( 2.5), with a decrease following antirejection
therapy. The activation markers HLA-DR and IL-2 receptor on T cells
were increased only during 3/12 rejection episodes. Patients with
rejections resistant to prednisone pulse therapy (N = 6) had signifi-
cantly more lymphocytes/mm3 in the peripheral blood (1111.7 597.5)
than successfully treated patients (N = 6, 336.7 196.0, P < 0.02).
Antirejection therapy with prednisone pulses and/or antithymocyte
globulin resulted in a significant decrease of T lymphocytes (CD3) with
a selective reduction of T helper/inducer cells (CD4I. Six months after
renal transplantation the patients had a higher percentage of suppressor!
cytotoxic cells (CD8I compared to the pretransplant values (26.3
10.9% vs. 17.7 6.2%, P < 0.02) and blood donors (16.3 6.2%, P <
0.01). Furthermore, the percentage of T helper cells (CD4/CD28i was
significantly higher and the T suppressor-inducer cells (CD4/CD28)
were significantly lower compared to the controls. Serial flow cytomet-
nc determinations of lymphocyte subsets in renal allograft recipients
may be helpful in some cases, although rejection episodes could not be
predicted in the individual patient.
Morphologic findings In zero-hour biopsies of renal grafts and signifi-
cance for early and late renal function. E. Curschell'zs, J. Landmann, B.
Huser, G. Thiel, V. Basler, F. Gudat, M.J. Mihatsch, Institut fur
Pat hologie Base!, Kantonsspita! Base!, Departement fur Chirurgie oder
Medizin, Base!, Switzerland. The extreme lack of renal grafts for
transplantation stimulated us to analyze how strict the selection criteria
for donor kidneys must be. We therefore investigated if preexisting
lesions in renal grafts had some influence for renal function. One
hundred and forty-seven zero-hour biopsies from 101 donors (mean age
33, from 6-64 years) were examined. A total of 38% of biopsies showed
no light microscopic changes, 44% showed nonspecific and 18% specific
lesions. Renal biopsies with nonspecific lesions had hyalinosis of
arterioles in 44%, a medium severe to severe interstitial fibrosis in 8%
and a medium severe to severe arteriolosclerosis in 29%. In 102
immunohistologically-examined biopsies, 74.5% showed nonspecific
lgM/C3 deposits in glomeruli and/or arterioles. A significant decrease of
normal renal biopsies was found with increasing age of dcrnors. This
decrease was most evident in donors older than 40 years. The cases
with specific findings consist of glomeruloscierosis (N = 4), glomeru-
lonephnitis (N = 11) and intravascular coagulation (N = 10). In cases
with nonspecific immunohistologic findings and in glomerulonephnitis it
was found in rebiopsies that antigen deposits disappeared within 4
months. Independent of morphologic findings, 82% of transplant recip-
ients had a good initial and late renal function. We coaclude that donor
age, hematuria or proteinuria, glomerulosclerosis, glomerulonephritis
or intravascular coagulation are no absolute contraindication for trans-
plantation of the kidney, if renal function of the donor was normal
immediately before transplantation.
Human recombinant erythropoietin (rIluEPO) in anemic patients on
maintenance hemodialysis (HD). Comparison between intravenous (i.v.)
and subcutaneous (s.c.) administration. C. Zehnder, A. B!umberg,
Kantonsspital, Aarau, Switzerland. rHuEPO is now an established
therapy for the anemia of HD patients (pts). Some questions remain as
to the optimal maintenance dose as well as to the route and frequency
of administration. In this prospective study, we tried to determine
whether s.c. rHuEPO at a reduced dosage was as effective as i.v.
rHuEPO in maintaining constant hemoglobin (Hb) levels. Twelve
anemic pts on HD previously treated with rHuEPO i.v. for 11.8 7.7
months (mean sn) were studied. For 3 months Hb was kept at a stable
level of 10 - 13 g/dl with individually titrated i.v. rHuEPO administered
thricc weekly after each HD. Pts were then switched to s.c. rHuEPO.
Initially, 50% of the previous weekly dose was given as twice weekly
s.c. injections. During the following 3 months the rHuEPO dosage was
adapted to maintain the target Hb level. Three pts did not complete the
second period, 2 because of severe anemia from intercurrent acute
pancreatitis and staphylococcal septicemia, respectively, requiring an
increase in dosage not compatible with the s.c. route; the third Pt who
was operated on (ileal conduit), also required larger quantities of
rHuEPO, developed pain at the s.c. injection site and was changed back
to i.v. rHuEPO. Nine of 12 pts completed the study. Their results are
summarized in the Table (means SD).
EPOi.v.
U/kg/wk
Hb
gld!
EPO
U/kg/wk
Hb
g/d!
I month 233 110 10.5 1.1 121 65 11.5 1.2
2 month 246 118 10.6 0.9 120 63 11.3 1.4
3 month 233 116 11.1 0.6 139 81 11.1 0.9
Conclusions: s.c. rHuEPO twice weekly was as effective at a lower
dose (50 to 60%) as i.v. rHuEPO thrice weekly, and had a very low
incidence of adverse reactions over the observation perioc of 3 months.
Recovery of renal function after initiation of chronic dialysis: clinical
aspects. S. David, J.P. Wauters, Division of Nephro!ogy, CHUV,
Lausanne, Switzerland. To delineate the respective importance of
different factors which may accelerate the natural history of chronic
nephropathies towards end-stage renal failure, the present study inves-
tigated the clinical evolution of patients able to stop their chronic
dialysis program due to partial recovery of renal function. Among a
total of 384 patients starting chronic dialysis in our unit between
January 1976 and June 1989, 16 patients (4.2%) were able to interrupt
their dialysis program due to an increase in residual renal function. This
group consisted of 9 males and 7 females, aged between 27 and 75 years
at the initiation of therapy. The etiology of their renal failure was
nephroangiosclerosis in 5 cases, analgesic nephropathy 4, chronic
glomerulonephritis 2, refiux nephropathy 1, Wegener's disease 1,
cortical necrosis 1, scleroderma 1, diabetic glomenulosclerosis I. Nine
patients suffered from malignant hypertension when dialysis therapy
was initiated. After a median of 6 months of dialysis (range 1-30), the
Abstracts
substitution therapy could be interrupted. The subsequent evolution
was as follows: 9 patients are still off dialysis, 4 patients died of
intercurrent illnesses, 3 patients had to resume dialysis after uncon-
trolled hypertension 1, general non-compliance 1 and untreated acute
pyelonephritis 1; the interruptive period lasted 31, 44 and 3 months,
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respectively. Therefore, it appears that therapy of malignant hyperten-
sion and stopping of analgesic abuse, are the single most frequent
factors allowing a recuperation of renal function. More preventive
efforts should be directed towards these factors before end-stage renal
failure is reached.
